iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting.

Autor:	Goldenson BH; Department of Medicine, Division of Regenerative Medicine, University of California, San Diego, La Jolla, CA, United States., Hor P; Department of Medicine, Division of Regenerative Medicine, University of California, San Diego, La Jolla, CA, United States., Kaufman DS; Department of Medicine, Division of Regenerative Medicine, University of California, San Diego, La Jolla, CA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2022 Feb 03; Vol. 13, pp. 841107. Date of Electronic Publication: 2022 Feb 03 (Print Publication: 2022).
DOI:	10.3389/fimmu.2022.841107
Abstrakt:	Treatment of cancer with allogeneic natural killer (NK) cell therapies has seen rapid development, especially use against hematologic malignancies. Clinical trials of NK cell-based adoptive transfer to treat relapsed or refractory malignancies have used peripheral blood, umbilical cord blood and pluripotent stem cell-derived NK cells, with each approach undergoing continued clinical development. Improving the potency of these therapies relies on genetic modifications to improve tumor targeting and to enhance expansion and persistence of the NK cells. Induced pluripotent stem cell (iPSC)-derived NK cells allow for routine targeted introduction of genetic modifications and expansion of the resulting NK cells derived from a clonal starting cell population. In this review, we discuss and summarize recent important advances in the development of new iPSC-derived NK cell therapies, with a focus on improved targeting of cancer. We then discuss improvements in methods to expand iPSC-derived NK cells and how persistence of iPSC-NK cells can be enhanced. Finally, we describe how these advances may combine in future NK cell-based therapy products for the treatment of both hematologic malignancies and solid tumors. Competing Interests: DK is a co-founder, board member and advisor to Shoreline Biosciences and has an equity interest in the company. DK also consults for Qihan Biotech and VisiCELL Medical for which he receives income and/or equity. DK also has patents in the area of iPSC-NK cells. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Goldenson, Hor and Kaufman.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu